ATE544747T1 - Erkennung von transmembranpotentialen durch optische verfahren - Google Patents

Erkennung von transmembranpotentialen durch optische verfahren

Info

Publication number
ATE544747T1
ATE544747T1 AT00984287T AT00984287T ATE544747T1 AT E544747 T1 ATE544747 T1 AT E544747T1 AT 00984287 T AT00984287 T AT 00984287T AT 00984287 T AT00984287 T AT 00984287T AT E544747 T1 ATE544747 T1 AT E544747T1
Authority
AT
Austria
Prior art keywords
reagent
membrane
cell
changes
potential
Prior art date
Application number
AT00984287T
Other languages
German (de)
English (en)
Inventor
Roger Tsien
Jesus Gonzalez
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE544747T1 publication Critical patent/ATE544747T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/66—Thiobarbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic System without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/02—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain containing an odd number of >CH- or >C[alkyl]- groups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/80—Fluorescent dyes, e.g. rhodamine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/805—Optical property
AT00984287T 1999-12-13 2000-12-12 Erkennung von transmembranpotentialen durch optische verfahren ATE544747T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/459,956 US6342379B1 (en) 1995-06-07 1999-12-13 Detection of transmembrane potentials by optical methods
PCT/US2000/033739 WO2001042211A2 (en) 1999-12-13 2000-12-12 Detection of transmembrane potentials by optical methods

Publications (1)

Publication Number Publication Date
ATE544747T1 true ATE544747T1 (de) 2012-02-15

Family

ID=23826844

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00984287T ATE544747T1 (de) 1999-12-13 2000-12-12 Erkennung von transmembranpotentialen durch optische verfahren

Country Status (7)

Country Link
US (4) US6342379B1 (US07087416-20060808-C00008.png)
EP (1) EP1409456B1 (US07087416-20060808-C00008.png)
JP (1) JP2003518246A (US07087416-20060808-C00008.png)
AT (1) ATE544747T1 (US07087416-20060808-C00008.png)
AU (1) AU783487B2 (US07087416-20060808-C00008.png)
CA (1) CA2393562C (US07087416-20060808-C00008.png)
WO (1) WO2001042211A2 (US07087416-20060808-C00008.png)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593135B2 (en) 1996-08-16 2003-07-15 The State Of Oregon, Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Long wavelength engineered fluorescent proteins
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
US7745142B2 (en) 1997-09-15 2010-06-29 Molecular Devices Corporation Molecular modification assays
US8012682B2 (en) * 1998-12-11 2011-09-06 Clontech Laboratories, Inc. Nucleic acids encoding chromophores/fluorophores and methods for using the same
US9834584B2 (en) * 1998-12-11 2017-12-05 Takara Bio Usa, Inc. Nucleic acids encoding chromophores/fluorophores and methods for using the same
US20030087492A1 (en) 2001-11-02 2003-05-08 Promos Technologies, Inc. Semiconductor device and method of manufacturing the same
EP1222257A4 (en) 1999-10-08 2007-12-12 Caliper Life Sciences Inc USE OF NERNST POTENTIAL SENSITIVE DYES TO MEASURE TRANSMEMBRANE POTENTIAL
EP1305412A2 (en) * 1999-10-14 2003-05-02 Clontech Laboratories Inc. Anthozoa derived chromo/fluoroproteins and methods for using the same
GB0012229D0 (en) * 2000-05-19 2000-07-12 Devgen Nv Lipid uptake assays
NZ525207A (en) * 2000-10-12 2006-05-26 Clontech Lab Inc Nucleic acids encoding stichodactylidae chromoproteins
CA2429769C (en) * 2000-12-07 2016-04-26 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
US6969597B2 (en) 2001-02-21 2005-11-29 Clontech Laboratories, Inc. Nucleic acids encoding non aggregating fluorescent proteins and methods for using the same
US7015310B2 (en) * 2001-03-12 2006-03-21 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Oxidation reduction sensitive green fluorescent protein variants
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US7060292B2 (en) * 2001-06-09 2006-06-13 Gesynthesis, Inc. Lipid structures and uses thereof
WO2002103321A2 (en) * 2001-06-14 2002-12-27 Anadys Pharmaceuticals, Inc. Methods of screening for ligands of target molecules
WO2003006606A2 (en) * 2001-07-09 2003-01-23 Oklahoma Medical Research Foundation Targeted fusion proteins and methods for the characterization of cellular membrane domains
US6852504B2 (en) 2001-08-08 2005-02-08 Molecular Devices Corporation Method for measuring cellular transmembrane potential changes
US20030082511A1 (en) * 2001-09-25 2003-05-01 Brown Steven J. Identification of modulatory molecules using inducible promoters
TW200406466A (en) * 2001-11-13 2004-05-01 Ciba Sc Holding Ag Compositions comprising at least one oxonol dye and at least one metal complex
CA2477780A1 (en) * 2002-03-05 2003-09-18 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
US20030228703A1 (en) * 2002-04-05 2003-12-11 The Regents Of The University Of Michigan Fluorescence resonance energy transfer quantitation and stoichiometry in living cells
US20030228566A1 (en) * 2002-06-11 2003-12-11 Biotechplex Corporation Method of and apparatus for screening for drug candidates
JP4429577B2 (ja) * 2002-09-30 2010-03-10 株式会社ニコン 細胞内反応測定装置および細胞内反応測定方法
US7432036B2 (en) * 2002-10-07 2008-10-07 Fujifilm Corporation Non-resonant two-photon absorbing material, non-resonant two-photon emitting material, and method for inducing absorption or generating emission of non-resonant two photons by using the material
AU2003285844A1 (en) * 2002-11-12 2004-06-03 Zakrytoe Aktsionernoe Obschestvo "Evrogen" Fluorescent proteins and chromoproteins from non-aequorea hydrozoa species and methods for using same
US7413874B2 (en) * 2002-12-09 2008-08-19 University Of Miami Nucleic acid encoding fluorescent proteins from aquatic species
KR20060002793A (ko) * 2003-03-03 2006-01-09 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Ｍｄａ-7을 포함하는 방법 및 조성물
CA2520664A1 (en) 2003-03-27 2004-10-14 Ptc Therapeutics, Inc. Targeting enzymes of the trna splicing pathway for identification of anti-fungal and/or anti-proliferative molecules
EP1613158A4 (en) 2003-03-27 2007-08-22 Ptc Therapeutics Inc METHOD FOR IDENTIFYING COMPOUNDS WITH A TRNA-SPLICEN ENDONUCLEASE AT THE PLACE OF ATTACK, AND USES THEREOF FOR PROVIDING THESE COMPOUNDS AS PROLIFERATION-INHIBITABLE AGENTS
WO2004094597A2 (en) * 2003-04-16 2004-11-04 University Of Miami Anthozoan fluorescent protein genes
JP2004357552A (ja) * 2003-06-03 2004-12-24 Hitachi Ltd 作用物質による効果推定方法及びスクリーニング方法
FR2858177A1 (fr) * 2003-07-28 2005-02-04 Genethon Utilisation du phenomeme fret, detecte par mplsm, pour le suivi in vivo d'evenements biologiques
US20050037364A1 (en) 2003-08-13 2005-02-17 International Business Machines Corporation Techniques for recording signals
US7125908B2 (en) * 2003-08-29 2006-10-24 Allergan, Inc. Treating pain using selective antagonists of persistent sodium current
US7060723B2 (en) * 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
US8034790B2 (en) * 2003-12-01 2011-10-11 Introgen Therapeutics Use of MDA-7 to inhibit pathogenic infectious organisms
GB0403616D0 (en) * 2004-02-18 2004-03-24 Univ Cambridge Tech Derivatised phospholipids
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
US20050260609A1 (en) * 2004-05-24 2005-11-24 Lapidus Stanley N Methods and devices for sequencing nucleic acids
GB0414653D0 (en) * 2004-06-30 2004-08-04 Univ Edinburgh Membrane fusion assay
US20060275310A1 (en) * 2004-09-30 2006-12-07 Nano Science Diagnostics, Inc. Method and detection and decontamination of antigens by nanoparticle-raman spectroscopy
TWI364882B (en) 2004-10-15 2012-05-21 Tyco Electronics Corp Connector system for conductive plates
KR101379364B1 (ko) * 2005-02-08 2014-03-31 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 암 치료를 위한 ｍｄａ-7을 포함하는 조성물
JPWO2006093252A1 (ja) * 2005-03-04 2008-08-07 国立大学法人 東京大学 膜アンカー型蛍光プローブ
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US20090093403A1 (en) 2007-03-01 2009-04-09 Feng Zhang Systems, methods and compositions for optical stimulation of target cells
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US10052497B2 (en) 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
JP2009502140A (ja) 2005-07-22 2009-01-29 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 光活性化陽イオンチャネルおよびその使用
EP1934610B1 (en) * 2005-10-12 2010-01-27 Allergan, Inc. Assays of molecular or subcellular interactivity using depolarization after resonance energy transfer (daret)
EP1803780B1 (en) * 2005-12-20 2009-03-25 Agfa Graphics N.V. Contrast dyes for inkjet lithographic printing plates
AU2007261108A1 (en) * 2006-06-19 2007-12-27 Highland Instruments, Inc. Apparatus and method for stimulation of biological tissue
US8892200B2 (en) 2006-06-19 2014-11-18 Highland Instruments, Inc. Systems and methods for stimulating tissue using focused energy
US9913976B2 (en) 2006-06-19 2018-03-13 Highland Instruments, Inc. Systems and methods for stimulating and monitoring biological tissue
US8155730B2 (en) * 2006-10-24 2012-04-10 The Research Foundation Of State University Of New York Composition, method, system, and kit for optical electrophysiology
US8398692B2 (en) 2007-01-10 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US8401609B2 (en) 2007-02-14 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
US7994786B2 (en) * 2007-06-19 2011-08-09 Mary Hitchcock Memorial Hospital System and method for use of nanoparticles in imaging and temperature measurement
WO2009018379A1 (en) * 2007-07-31 2009-02-05 Purdue Pharma L.P. Dielectric spectroscopy assays for screening of ion channel ligands
JP4604187B2 (ja) * 2007-08-14 2010-12-22 独立行政法人産業技術総合研究所 糖鎖を介したルシフェラーゼと有機蛍光色素間のエネルギー移動を利用した可視−近赤外光プローブ
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
US10035027B2 (en) 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
EP2062944A1 (en) * 2007-11-20 2009-05-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Water-soluble rylene dyes, methods for preparing the same and uses thereof as fluorescent labels for biomolecules
ES2608498T3 (es) 2008-04-23 2017-04-11 The Board Of Trustees Of The Leland Stanford Junior University Sistemas, métodos y composiciones para la estimulación óptica de células diana
CA2726128C (en) 2008-05-29 2016-10-18 The Board Of Trustees Of The Leland Stanford Junior University Cell line, system and method for optical control of secondary messengers
US8956363B2 (en) 2008-06-17 2015-02-17 The Board Of Trustees Of The Leland Stanford Junior University Methods, systems and devices for optical stimulation of target cells using an optical transmission element
EP2303405A4 (en) 2008-06-17 2017-12-27 The Board of Trustees of the Leland Stanford Junior University Apparatus and methods for controlling cellular development
WO2010006049A1 (en) 2008-07-08 2010-01-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
US20100029017A1 (en) * 2008-07-29 2010-02-04 Becton, Dickinson And Company Mono-chlorinated hydroxycoumarin conjugates
WO2010017392A2 (en) * 2008-08-07 2010-02-11 Highland Instruments, Inc. Interface apparatus for stimulation of biological tissue
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
US8431416B2 (en) * 2009-04-01 2013-04-30 Becton, Dickinson And Company Reactive heterocycle-substituted 7-hydroxycoumarins and their conjugates
WO2011087789A2 (en) 2009-12-22 2011-07-21 Becton, Dickinson And Company Methods for the detection of microorganisms
JP5866332B2 (ja) 2010-03-17 2016-02-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 感光性イオンを通過させる分子
DE102010012857B4 (de) * 2010-03-25 2015-02-19 Tim Liedl Vorrichtung zum Erfassen einer Weggröße
US20140148726A1 (en) 2010-10-21 2014-05-29 Timothy Andrew WAGNER Methods for detecting a condition
AU2011323228B2 (en) 2010-11-05 2016-11-10 The Board Of Trustees Of The Leland Stanford Junior University Control and characterization of memory function
CN106947741A (zh) 2010-11-05 2017-07-14 斯坦福大学托管董事会 光活化嵌合视蛋白及其使用方法
EP2635346B1 (en) 2010-11-05 2017-03-29 The Board of Trustees of the Leland Stanford Junior University Optogenetic control of reward-related behaviors
CA2816968C (en) 2010-11-05 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Optically-controlled cns dysfunction
US10568307B2 (en) 2010-11-05 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Stabilized step function opsin proteins and methods of using the same
CN110215614A (zh) 2010-11-05 2019-09-10 斯坦福大学托管董事会 用于光遗传学方法的光的上转换
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
US8594783B2 (en) 2011-08-24 2013-11-26 Highland Instruments, Inc. Systems and methods for stimulating cellular function in tissue
WO2013090356A2 (en) 2011-12-16 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
AU2013222443B2 (en) 2012-02-21 2017-12-14 Circuit Therapeutics, Inc. Compositions and methods for treating neurogenic disorders of the pelvic floor
WO2013130808A1 (en) 2012-02-29 2013-09-06 D.E. Shaw Research, Llc Methods for screening voltage gated proteins
BR112015013403A2 (pt) * 2012-12-11 2017-07-11 Clarient Diagnostic Services Inc métodos para sondar alvos múltiplos em uma amostra biológica, para analisar amostra biológica de multiplexação de alto rendimento e para usar um kit, série de pelo menos duas imagens que representam alvos biológicos opticamente marcados, kit para alvejar um sinal para sondar alvos múltiplos em uma amostra biológica, e, processo automatizado para alvejamento químico fotoativado de uma amostra biológica
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
WO2014144409A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of behavioral state
AU2014260101B2 (en) 2013-04-29 2018-07-26 Humboldt-Universitat Zu Berlin Devices, systems and methods for optogenetic modulation of action potentials in target cells
US8933239B1 (en) 2013-07-16 2015-01-13 Dow Global Technologies Llc Bis(aryl)acetal compounds
US9063420B2 (en) 2013-07-16 2015-06-23 Rohm And Haas Electronic Materials Llc Photoresist composition, coated substrate, and method of forming electronic device
US8962779B2 (en) 2013-07-16 2015-02-24 Dow Global Technologies Llc Method of forming polyaryl polymers
US9410016B2 (en) 2013-07-16 2016-08-09 Dow Global Technologies Llc Aromatic polyacetals and articles comprising them
JP6621747B2 (ja) 2013-08-14 2019-12-18 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 疼痛を制御するための組成物及び方法
CN104101589B (zh) * 2014-07-29 2016-04-27 重庆大学 基于tmrm的细胞静息膜电位和钠钾离子通透性比值检测方法
USD759803S1 (en) 2014-10-28 2016-06-21 Highland Instruments, Inc. Adjustable headpiece with anatomical markers
WO2016205027A1 (en) * 2015-06-15 2016-12-22 Oklahoma Medical Research Foundation Ubiquitin interacting motif peptides as therapeutics
WO2016209654A1 (en) 2015-06-22 2016-12-29 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
EP3574328B1 (en) 2017-01-30 2021-12-01 The Government of the United States of America, as represented by the Secretary of the Navy Modular, multifunctional nanoparticle-based bioconjugate for realtime visualization of cellular membrane potential
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture
CN107118127B (zh) * 2017-06-28 2019-01-04 哈尔滨理工大学 氨基酸席夫碱及其合成方法与应用
WO2020083398A1 (zh) * 2018-10-26 2020-04-30 山东大学 细胞特异性光敏效应的实时筛查与测量系统及方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE43619C (de) * 1887-06-25 1888-06-23 C. RAAB in Kaiserslautern Calorimetrischer Elektricitätszähler
US3480436A (en) * 1966-08-29 1969-11-25 Eastman Kodak Co Antihalation compositions containing pentamethine oxonol dyes in aromatic alcohols
JPS59218956A (ja) 1983-05-27 1984-12-10 Fujirebio Inc 膜融合測定方法
ES8607563A1 (es) 1983-10-13 1986-06-01 Univ Georgia Res Found Un metodo para detectar una interaccion ligante
US4861727A (en) 1986-09-08 1989-08-29 C. R. Bard, Inc. Luminescent oxygen sensor based on a lanthanide complex
US4900934A (en) 1987-07-15 1990-02-13 University Of Utah Apparatus for simultaneous visualization and measurement of fluorescence from fluorescent dye-treated cell preparations and solutions
EP0502843A1 (en) * 1988-11-25 1992-09-16 BENNER, Richard L Process and apparatus for the detection of sulfur
AT393035B (de) 1989-04-25 1991-07-25 Avl Verbrennungskraft Messtech Verfahren zur quantitativen bestimmung zumindest eines chemischen parameters eines probenmediums
DK0429907T3 (da) 1989-11-21 1994-10-03 Bayer Ag Optisk biosensor
US5244813A (en) 1991-01-25 1993-09-14 Trustees Of Tufts College Fiber optic sensor, apparatus, and methods for detecting an organic analyte in a fluid or vapor sample
DE4121426A1 (de) 1991-06-28 1993-01-14 Basf Ag Chemischer sensor
CA2087412A1 (en) 1992-01-17 1993-07-18 Joseph R. Lakowicz Ph and pco2 sensing by luminescent lifetimes and energy transfer
DE69333073T2 (de) 1992-02-12 2004-04-15 Chromagen, Inc., San Diego Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen
WO1995008637A1 (en) 1993-09-21 1995-03-30 Washington State University Research Foundation Immunoassay comprising ligand-conjugated, ion channel receptor immobilized in lipid film
GB9406464D0 (en) 1994-03-31 1994-05-25 British Tech Group Assay for determining biochemical changes at phospholipid bilayer membrane surfaces
US5661035A (en) * 1995-06-07 1997-08-26 The Regents Of The University Of California Voltage sensing by fluorescence resonance energy transfer
AU5090498A (en) 1997-01-07 1998-08-03 California Institute Of Technology Optical sensors of cell signaling

Also Published As

Publication number Publication date
US7118899B2 (en) 2006-10-10
EP1409456A2 (en) 2004-04-21
US7173130B2 (en) 2007-02-06
AU783487B2 (en) 2005-11-03
EP1409456B1 (en) 2012-02-08
CA2393562A1 (en) 2001-06-14
AU2093001A (en) 2001-06-18
CA2393562C (en) 2015-10-27
WO2001042211A3 (en) 2002-01-17
US7087416B2 (en) 2006-08-08
US20020164577A1 (en) 2002-11-07
JP2003518246A (ja) 2003-06-03
WO2001042211A2 (en) 2001-06-14
US20040002123A1 (en) 2004-01-01
US20030207248A1 (en) 2003-11-06
US6342379B1 (en) 2002-01-29

Similar Documents

Publication Publication Date Title
ATE544747T1 (de) Erkennung von transmembranpotentialen durch optische verfahren
ATE186400T1 (de) Erkennung von transmembranpotentialen durch optische verfahren
Ryan Presynaptic imaging techniques
CN101151378B (zh) 规定部位发光量测定方法、规定部位发光量测定装置、表达量测定方法及测定装置
JP5073491B2 (ja) 分析対象物の検出のための方法
CN101438147B (zh) 生物试样摄像方法及生物试样摄像装置
DE60002562D1 (de) Ein system für zellbasierte reihenuntersuchungen
Zhang et al. Single-molecule imaging of NGF axonal transport in microfluidic devices
WO2001071350A3 (en) Methods of registering trans-membrane electric potentials
JP2004533853A (ja) 光合成阻害を検出する装置および方法
Seebach et al. Quantitative dynamics of VE-cadherin at endothelial cell junctions at a glance: basic requirements and current concepts
US20210350875A1 (en) High throughput method and system for mapping intracellular phase diagrams
Denner et al. High-content analysis in preclinical drug discovery
Ulbrich Counting molecules: Toward quantitative imaging
Spatola Rossi et al. FRET‐FLIM to Determine Protein Interactions and Membrane Topology of Enzyme Complexes
US20130005042A1 (en) Hybrid single molecule imaging sorter
Greig et al. Fluorescence recovery after photobleaching to study the dynamics of membrane-bound proteins in vivo using the Drosophila embryo
DE69426965T2 (de) Test zum Nachweis von Toxizität
Sott et al. Optical systems for single cell analyses
Foo et al. Fluorescence correlation and cross-correlation spectroscopy using fluorescent proteins for measurements of biomolecular processes in living organisms
JP4839073B2 (ja) 微弱光解析方法
Patterson et al. Developing photoactivated localization microscopy (PALM)
MX9709597A (es) DTECCIaN DE POTENCIALES DE TRANSMEMBRANA MEDIANTE MÉTODOS aPTICOS.
UA134575U (uk) Спосіб проведення моніторингу впливу хімічних речовин на біоорганізми у кількох інтервалах часу
Ohara-Imaizumi et al. Imaging of Insulin Exocytosis from Pancreatic Beta Cells